Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly and Company (LLY) announced exploratory Phase 3b results comparing combined Taltz and Zepbound treatment with Taltz alone in psoriasis.
The TOGETHER-PsO analysis covered adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related condition. Broader changes in biomarkers—measurable biological indicators—appeared with combined treatment as early as Week 12. By Week 36, changes involved 482 versus 140 proteins and 467 versus 16 genes. Combined treatment also showed greater reductions in inflammatory immune activity.
Previously reported results showed superior skin clearance and clinically meaningful weight reduction versus Taltz alone at Week 36, with improvements maintained or further improved through Week 52. Safety was consistent with each medicine's known profile. The randomized study enrolled 274 participants.
Eli Lilly and Company (NYSE: LLY) will present 21 dermatology posters at Fall Clinical 2026, taking place October 8–11 in Las Vegas.
Thirteen EBGLYSS presentations cover atopic dermatitis, including durable adolescent responses with every-eight-week maintenance dosing, reduced flare rates and less topical treatment use. Phase 3 ADorable-1 presentations include investigational efficacy and safety findings in children aged six months and older through Week 16. Six presentations address concomitant Taltz and Zepbound use, including an exploratory TOGETHER-PsO biomarker analysis in adults with psoriasis and obesity or overweight with at least one weight-related comorbid condition. Olumiant's BRAVE-AA-PEDS results report sustained efficacy through 1.5 years and consistent safety up to a maximum of 2.5 years in adolescents with severe alopecia areata.
Eli Lilly and Company (LLY) received FDA approval for Jaypirca as a first-line treatment for certain adults with previously untreated CLL/SLL. The expanded indication covers chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion, a genetic change.
In the Phase 3 BRUIN CLL-313 trial, at a median follow-up of 28 months, Jaypirca improved progression-free survival, the time without disease progression, versus bendamustine plus rituximab (HR=0.20; p<0.0001). Median progression-free survival was not yet reached with Jaypirca versus 33.5 months with the comparator. Overall response rates were 94% versus 81%; complete response rates were 13% versus 21%. Serious adverse reactions occurred in 28% of Jaypirca patients; adverse reactions caused permanent discontinuation in 4.3%. Label warnings include infections, bleeding, low blood-cell counts, heart rhythm disorders, second cancers, liver injury and fetal harm.
Eli Lilly and Company (LLY) announced analyses linking Foundayo to lower predicted long-term diabetes and cardiovascular risk in adults with obesity or overweight.
The post-hoc analyses, conducted after the Phase 3 ATTAIN-1 trial, modeled 10-year risk at 72 weeks rather than reporting observed disease prevention. Estimated type 2 diabetes risk reductions versus placebo were 45%, 50% and 57% for Foundayo 5.5 mg, 9 mg and 17.2 mg, respectively. Estimated cardiovascular disease risk reductions were 13%, 15% and 18% at those doses.
ATTAIN-1 randomized 3,127 participants without diabetes who had obesity or overweight with a qualifying medical condition. The analyses were published in Diabetes, Obesity and Metabolism. Foundayo is FDA-approved for weight reduction and long-term weight maintenance in eligible adults, alongside a reduced-calorie diet and increased physical activity.
Eli Lilly (LLY) reported that Foundayo met the cardiovascular safety objective in ACHIEVE-4, its Phase 3 type 2 diabetes trial. The study randomized 2,749 adults with obesity or overweight and increased cardiovascular risk. Compared with insulin glargine, Foundayo showed 16% lower risk of major cardiovascular events including hospitalization for unstable chest pain, meeting the prespecified non-inferiority criterion, rather than establishing superiority.
At 52 weeks, A1C, a measure of longer-term blood sugar, fell 1.6% versus 1.0%; weight fell 8.8% versus a 1.7% gain. Pre-planned analyses showed 53% lower cardiovascular death risk and 57% lower all-cause death risk, but were not adjusted for multiple statistical tests. Adverse events led 10.6% of Foundayo participants to discontinue during the 52-week minimum treatment period. Foundayo is approved for weight management; its use for type 2 diabetes remains under study.
Eli Lilly (LLY) reported that its investigational EloraTZP combination met primary and secondary endpoints in a Phase 2b obesity and diabetes trial. The 48-week study enrolled 367 adults with obesity or overweight and type 2 diabetes. EloraTZP combines eloralintide and tirzepatide. At the 9 mg/15 mg combination dose, average weight loss was 23.3% (54.1 lbs), versus 14.8% (34.4 lbs) with tirzepatide 15 mg. A1C, a measure of blood sugar, fell 2.9% versus 2.4%. The primary endpoint compared weight change with placebo; other comparisons were secondary endpoints.
Gastrointestinal adverse events were generally mild or moderate but more frequent with combinations. Adverse-event discontinuations were 10.8% to 27.0% with EloraTZP versus 2.9% with tirzepatide. Lilly plans Phase 3 trials of a co-formulation by the end of 2026, using an optimized dose-escalation schedule.
Eli Lilly (LLY) reported that EBGLYSS monotherapy met the primary and secondary endpoints in its Phase 3b hand-and-foot atopic dermatitis study. ADtouch enrolled 221 adults and adolescents and compared treatment every two weeks with placebo over 16 weeks. At Week 16, 53% versus 27% achieved clear or almost clear hands and feet with at least a two-point improvement on the physician assessment.
Among patients with baseline symptom scores of at least four, four-point itch improvement occurred in 57% versus 19%, and pain improvement in 59% versus 19%. Among patients initially dissatisfied with hand clearance, 77% versus 40% were satisfied or very satisfied at Week 16. Adverse events occurred in 41.8% versus 39.6%; all were mild or moderate, with no new safety signals. Lilly submitted the data to the FDA and plans submissions to select global regulators for a potential label update.
Eli Lilly and Company (LLY) reported Phase 3 TRIUMPH-2 results showing retatrutide reduced weight in adults with type 2 diabetes and obesity or overweight. At 80 weeks, average weight loss was 12.7%, 19.1% and 20.8% with 4 mg, 9 mg and 12 mg, respectively, versus 4.0% with placebo. A1C, a measure of average blood sugar, fell 1.4%, 1.6% and 1.5%, respectively, versus 0.2% with placebo.
With 12 mg, 59.5% no longer met obesity BMI criteria; participants starting with BMI of 35 or higher lost an average of 60.8 lbs. Cardiovascular risk measures also improved. Adverse-event discontinuations were 3.8%, 11.6% and 7.7% across ascending doses, versus 4.9% with placebo. Results estimate efficacy assuming participants remained on treatment without prohibited weight-management treatments or, for blood-sugar endpoints, rescue therapy. Lilly plans to submit a U.S. marketing application in Q1 2027.
Eli Lilly (LLY) reported an indirect comparison associating Zepbound 10 mg and 15 mg with greater weight loss than Wegovy HD. The analysis drew on SURMOUNT-1 and STEP UP data from adults with obesity. At 72 weeks, the treatment-regimen analysis associated Zepbound 15 mg with 4.5% greater average body-weight loss than Wegovy HD 7.2 mg, and Zepbound 10 mg with 3.2% greater loss.
For Zepbound 15 mg, the odds of losing at least 20% of body weight were 3.54 times those with Wegovy HD under the treatment-regimen measure and 4.15 times under the efficacy measure. Efficacy-based average weight-loss differences of 1.8% for 15 mg and 0.7% for 10 mg did not reach statistical significance. Neither did the higher estimated odds of at least 20% weight loss with 10 mg. Discontinuation due to adverse events was comparable across treatments.
Eli Lilly (LLY) reported an indirect comparison showing greater weight loss and A1C reduction with Foundayo than with oral semaglutide. At 52 weeks, Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg in adults with type 2 diabetes. A1C measures long-term blood sugar. The analysis used data from the ACHIEVE-3 and PIONEER PLUS trials, rather than a direct trial of those two doses.
In the separate ACHIEVE-3 head-to-head trial, Foundayo 17.2 mg reduced A1C by 2.2% and body weight by 9.2% at 52 weeks, versus 1.4% and 5.3%, respectively, with oral semaglutide 14 mg. Foundayo 9 mg also showed greater reductions than oral semaglutide 7 mg. Foundayo is approved in the United States for weight management in eligible adults and is being studied as a potential type 2 diabetes treatment. Oral semaglutide 25 mg is not approved there for type 2 diabetes.